Growth Strategy (Second Medium-Term Management Plan)

The environment surrounding the pharmaceutical industry is rapidly changing, and in new drug development and the healthcare field, there are various growth opportunities such as the increasing activity of open innovation, the creation of new value through collaboration with different industries, and the rising importance of self-medication. We aim to become a globally competitive company that can respond flexibly and swiftly to any situation by implementing four growth strategies: Maximization of product value – From a patient-centered perspective –, Reinforcement of pipelines, Acceleration of global business advancement, and Expansion of business domains. Furthermore, we are striving to enhance our intangible assets that serve as the management foundation supporting these growth strategies, including our digital and IT infrastructure, human capital, and corporate brand.

Strengthen the Management Foundation and Implement the Four Growth Strategies

▽ Maximization of product value - From a patient-centered perspective -
We will work together with healthcare professionals to realize the wellbeing of patients and their families (a state of fulfillment in terms of physical, mental, social, and life satisfaction), and as a result, we will strive to achieve the rapid penetration of new drugs into medical treatment facilities.
In marketing, we are working to develop human talents who, in collaboration with healthcare professionals, address medical issues from the patient’s perspective and who use digital technologies to effectively and efficiently provide and collect information, thereby maximizing product value.
In development, we have conducted nearly 100 clinical trials, mainly in our key strategic fields of oncology, and we continue to aim to maximize product value.

▽ Reinforcement of pipelines
We aim to become a “Global Specialty Pharma” by accumulating disease know-how and working on creating innovative new drugs in areas of high medical need such as oncology, immunology & inflammation and neurology, We will strengthen research and drug discovery partnerships with world-leading universities, research institutions, and biotech venture companies, and strive to expand highly original pipelines that can aim for first-in-class. In addition, we select optimal drug discovery modalities according to the drug discovery seeds, advance highly unique in-house drug discovery, and enhance reliability of research and development by using data from nonclinical and clinical studies to verify drug targets and strengthen translational research. Further, we are working to strengthen our pipelines by aggressively introducing innovative compounds and acquiring new technologies in the areas with high medical needs.

▽ Acceleration of global business advancement
We are working to expand our global business to deliver new drugs around the world. To expand and accelerate our overseas business, we acquired Deciphera to obtain sales structure in the US and Europe as well as to strengthen our pipelines and R&D capabilities. In addition, we are working to reorganize and integrate our conventional US and UK functions with Deciphera as the base for our US and European operations. Our group will work together to further accelerate our global business. In the short-term, we will maximize the product value of QINLOCK and ROMVIMZA through additional indications and expansion of sales territories and promote activities for the launch of ONO-4059 (Velexbru Tablets) in the US. We will also work to strengthen our global development organization and promote development in the US and Europe, not only in oncology area but also in other disease areas. We will continue our efforts to deliver innovative medicines to more patients around the world as quickly as possible.

▽ Expansion of business domains
We are committed to expanding our business domains to capture the needs of the expanding healthcare sector and continue to deliver new value. We are continuously expanding our customers for our sleep supplement, REMWELL, as foods with functional claims. In addition to ‘michiteku β-version’, a tool to support psychological care for cancer (colorectal, gastric, lung, and breast cancer) patients immediately after being informed and improvement of their health care literacy to understand what doctors tells, we started, in January 2025, to provide ‘michiteku YOHA’, an application for managing hospital visit days to support balancing between daily life and treatment. In parallel with these activities, we aim to create and expand new businesses through investment activities in healthcare startups by ONO DIGITAL HEALTH INVESTMENT, GK.

▽ Corporate Transformation through Digital & IT
We promote the use of digital and IT technology cross-functionally, aiming to transform into a company capable of accerelating growth strategies, innovating business process, and realizing new value creation (DX) . This requires a flexible IT infrastructure supported by data utilization platform including internal and external data, the capability of data analysis from our unique perspectives, and the latest technologies.The utilization of internal and external data enables us to detect and assess business issues and new opportunities accurately and in a timely manner and turn them into business transformation initiatives.

▽ Management Infrastructures to Support Growth Strategies – Expansion of Intangible Assets –
Expanding our intangible assets: human capital, corporate brand, digital and IT infrastructure, etc. will support our four growth strategies, and help us achieve dramatic growth. In the expansion of human capital, we are working on securing and developing human resources to promote business growth, while also building an organizational culture to achieve high employee engagement. Regarding our corporate brand, we will work to enhance corporate value by working with Deciphera to promote the penetration of our brand at global levels.